

## DAFTAR PUSTAKA

- Alberti K, Zimmet P, Shaw J, 2007. International Diabetes Federation : a consensus on type 2 Diabetes prevention. *Diabetic Medicine*; 24: 451-63
- Antonio C, Endricco U, 2004. Oxidative Pathogenic Mechanism Underlying Insulin Resistance, Diabetes and Cardiovascular Disease. *Diabetes J* : 43 ; 1234-45.
- Addabbo F, Montagnani M, Goligorsky MS, 2009. Mitochondria and reactive oxygen species. *Hypertension*; 53 : 885-92
- Ahren B, Schmitts O, 2004. GLP-1 receptor agonist and DPP -4 Inhibitors in treatment of type 2 diabetes. *Horm Metab Res*; 36 (11-12):867-76.
- Alwi I, 2011. Pencegahan Komplikasi Makrovaskuler : Silent Myocardial Infarction pada Diabetes Tipe 2. Dalam : Buku Tatalaksana Holistik Penyakit Kardiovaskuler; p 1-10. Internal Publishing, Jakarta.
- Brownlee M, 2000. Negative consequences of glycation. *Metabolism Clinical and Experimental* 49: S9-S13.
- Brownlee M, 2001. Biochemistry and molecular cell biology of diabetic complications. *Nature*; 414:813-20
- Brownlee M, 2005. The pathology of diabetic complication. A unifying mechanism. *Diabetes*; 54: 1615-25.
- Brownlee M, Hirch IB. 2006. Glycemic variability : a haemoglobin A1c independent risk factor for diabetic complication. *Jama* ; 295 (14):1707-8
- Borg R, Kuenen JC, Carstensen B, et al., 2010. Real-life glycemic profiles in non-diabetic individuals with low fasting glucose and normal HbA1c : the A1c-derived Average Glucose (ADAG) study. *Diabetologia* ;53: 1608-11
- Bouchard VJ, 2003. PARP-1 a determinant of Cell Survival in Response to DNA damage. Health and environment Unit, Laval University Medical Research Center. Sie foy Quebec Canada. *Experimental Hematology* ;31: 446-54. Published by Elsevier Inc.
- Bandeira E, 2013. Oxidative Stress as an Underlying Contributor in the Development of Chronic Complications in Diabetes Mellitus. *Int J Mol. Sci* : 14: 3265-84

- Beckman JS, Beckman TW, Chen J, et al., 1990. Apparent hydroxyl radical production by peroxynitrite : implication for endothelial injury from nitric oxide and superoxide. *Proc Natl acad Sci USA* 87: 1620-24
- Bonetti, PO, Lerman LO, Lerman A, 2003. Endothelial dysfunction : a marker of atherosclerotic risk. *Arterioscler. Thromb. Vasc. Biol*; 23: 168-75
- Bekman JA, Creager MA, Libby P, 2002. Diabetes and atherosclerosis : epidemiology, pathophysiology and management. *JAMA*; 15: 2570-81
- Bloomgarden ZT, 2003. Cardiovascular disease and diabetes. *Diabetes Care*; 26: 230-37.
- Buse J, Hart K, Minasi L, 1998. The PROTECT study: final results of a large multicenter postmarketing study in patients with type 2 diabetes. *Precose Resolution of optimal Titration to enhance Current Therapies. Clin Ther*;20: 2072-77
- Bucala R, Makita Z, Vega G et al., 1994. Modification of Low Density Lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. *Proc Natl Acad Sci USA*; 91: 9441-45
- Biondi-Zoccai GCL, Abbate A, Liuzzo G, et al., 2003. Atherosclerosis, inflammation and diabetes. *J Am Coll Cardiol*; 41:1071-77.
- Ceriello A, 1998. The emerging role of postprandial hyperglycemic spikes in the pathogenesis of diabetic complications. *Diabetetic Medicine* 15: 188-193.
- Ceriello A, Bais B, Quagliaro L et al., 2002. Role of Hyperglycemia in Nitrotyrosine Postprandial Generation. *Diabetes Care* ; 25 ( 8): 1439-43
- Ceriello A, 2005. Postprandial hyperglycemia and diabetes complications : is it time to treat ? *Diabetes* ; 54: 1-7
- Ceriello A, 2008. Cardiovascular effects of acute hyperglycemia : pathophysiological underpinnings. *Review. Diabetes Vasc Dis Res*; 5:260-68
- CN Chan J, Malik V, Jia W et al, 2009. Diabetes in Asia, Epidemiology, risk factors and pathophysiology. *Review. JAMA*;301(20):2129-40

Chen T, Xu F, Jin-bin Su, Wang X, Chen J et al, 2013. Glycemic variability in relation to oral disposition index in subjects with different stages of glucose tolerance. *Diabetology & Metabolic Syndrome*, 5 :38. Download from [www.dmsjournal.com/content/5/1/38](http://www.dmsjournal.com/content/5/1/38) on June 10, 2014

Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, 2002. Acarbose for the prevention of type 2 diabetes mellitus ; the STOP-NIDDM randomized trial. *Lancet* ;359: 2072-77

Christophe Ame J et al., 2004. The PARP superfamily. Review article. *Biossays Wiley Periodical Inc.*:26: 882-93

Cooper ME, Bonnet F, Oldfield M et al., 2001. Mechanism of diabetic vasculopathy : an overview. *AJH*; 14:475-86

DEPKES, 2008. Riset Kesehatan Dasar di Indonesia.

DEPKES, 2012. Riset Kesehatan Dasar di Indonesia.

DECODE Study group '1999. Is fasting glucose sufficient to define diabetes ? Epidemiological data from 20 European studies. *Diabetologia*; 42: 647-54

Dubois M, Vacher P, Roger B, 2007. Glucotoxicity inhibit late step of insulin exocitosis;148

De Souza BM, Assmann TS, Kliemann LM, et al., 2011. The role of uncoupling protein 2 (UCP2) on the development of type 2 diabetes mellitus and its chronic complication. *Arq Bras Endocrinol Metab*; 55 (4): 239-48

Echtay KS, Roussel D, St Pierre J et al., 2002. Superoxide activates mitochondrial uncoupling proteins. *Nature*;415:96-99

Endemann DH, Arendshorst WJ, 2004. Endothelial dysfunction. *J Am Soc. Nephrol*;15:1983-92

Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol In Adults ( Adult Treatment Panel III) *JAMA*; 2001 285:2486-97

Funk J, 2006. Disorder of endocrine pancreas. In : Mc Pee S, Lingappa V, Pathophysiology of Disease : an introduction to clinical medicine, 5<sup>th</sup>ed, Mc Graw Hill. New York.

Fauci A, Kasper D, Longo D, 2008. Harrison' s Principle of Internal Medicine. Mc Graw- Hill Companies. USA

Fowler, MJ, 2008. Microvascular and macrovascular complication of diabetes. Clin. Diabetes; 26: 77-82

Feletou M, Vanhoutte PM, 2006. Endothelial dysfunction : a multifaceted disorder. Am J Physiol.Heart Circ Physiol ; 291: H985-H 1002

Gerich JE,1998. The genetic basic of type 2 diabetes mellitus : impaired insulin secretion versus impaired insulin sensitivity. Endocrine Reviews 19 : 491-503

Guyton A and Hall J, 2006. Textbook of medical physiology. 11<sup>th</sup>ed, Philadelphia.

Gani M and Christopher JC, 2006. Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance. Diabetes Care; 55

Halliwell B and Gutteridge, 2004. Free radicals in Biology Medicine. Departementnof Biochemistry, Osaka University Medical School, 3<sup>rd</sup> ed. Oxford University Press.

Hanefeld et al.,2004. Alpha Glucosidase Inhibitors for patients with type 2 Diabetes Mellitus. Eur Heart J;25: 10-16

Hanefeld M, Cagatay M, Petrowitsch T, et al., 2004. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients : meta-analysis of seven long-term studies. Eur Heart J;25: 10-16.

Hurst TD, Lee RW, 2003. Increased incidence of coronary artry atherosclerosis in type 2 diabetes mellitus : mechanisms and management. Ann Intern Med; 139: 824-34

Hanefeld M, Chiasson JL, Koehler C, et al., 2004. Acarbose slows progression of intima-media thickness of carotic arteries in subjects with impaired glucose tolerance. Stroke;35:1073-78

Haffner S. 1997. Defining the problem of glucose toxicity in type 2 diabetes. Glucosetoxicity : Clinical implication for type 2 diabetes ; 4-6.

Haffner SM, Lehto S, Ronnemaa T, et al., 1998. Mortality from coronary heart diseases in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med; 339: 229-34

Hirsch IB, 2005. Glycemic variability, it's not just about A1c anymore. Diabetes Technol Ther; 7(5): 780-83

Hirsch IB, Brownlee M 2005. Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complication; 19 (3 ): 178-81

Heine RJ, Van Gaal LF, Johns D et al., 2005. For the GWAA study group : Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann Intern Med; 143 : 559-69

Hirose A, Tanikawa T, Mori H, et al., 2010. Advanced glycation endproducts increase endothelial permeability through the RAGE / Rho signaling pathway, FEBS let ; 584: 61-66

Highlander P, Shaw GP, 2010. Current pharmacotherapeutic concepts for the treatment of cardiovascular disease in diabetes. Therap. Adv Cardiovasc. Dis; 4: 43-54

Holman RR, Paul SK, Bethel MA et al., 2008 10-Years Follow up of Intensive glucose control in Type 2 Diabetes. N Engl J Med; 359: 1577-89

International Diabetes Federation , 2012. Online [http:// www.diabetesatlas.org](http://www.diabetesatlas.org). ( diakses April 2012)

International Diabetes Federation , 2013. Online [http:// www.diabetesatlas.org](http://www.diabetesatlas.org). (diakses Pebruari 2014)

IDF Guideline for Management of Postprandial Glucose . 2007. Diakses dari [www. Idf.org](http://www.Idf.org)

Inoue I, Shinoda Y, Nakano T, Sassa M, Goto S, Awata T, et al., 2006. Acobose ameliorates atherogenicity of low-density lipoprotein in patients with impaired glucose tolerance. Metabolism; 55: 946-52

Jonas JC, Sharma A, Hasenkamp W, 1999. Chronic hyperglycemia triggers loss of pancreatic. *Biological Chemistry* : 274; 14112-21.

Krauss S, Zang CY, Scorrano L et al., 2003. Superoxide mediated activation on uncoupling protein 2 causes pancreatic beta cell dysfunction. *J Clin Invest*;112: 1831-42

Kannel WB, Mc Gee DL,1979.Diabetes and cardiovascular disease: the Framingham study. *JAMA*; 241: 2035-38

Lyll F, Gibson JL, Greer IA et al., 1998. Increased nitrotyrosine in the diabetic placenta : evidence for oxidative stress. *Diabetes Care* ;21: 1732-58

Lebovitz HE, 2001. Effect of postprandial state on non traditional risk factors. *Am J Cardiol*; 88(suppl.): 20H-25H.

Mertes G, 2000. Safety and Efficacy of acarbose in the treatment of type 2 diabetes: data from a 5 years surveillance study. *Diabetes Res Clin Pract*; 52:193-204.

Monnier,2003. Contributions of Fasting and Postprandial Plasma Glucose Increments to Overall Diurnal Hyperglycemia of Type 2 Diabetes Mellitus Patients. *Diabetes Care*; 26: 881-85

Monnier L,2006. Beyond Hb1c in diabetes: The glucose tetrad for quiding therapy. *JAMA*; 295:1681-87.

Monnier L, Mas E, Ginet C, et al., 2009. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. *JAMA*; 295: 1681-87

Monnier L, Colette C, 2008. Glycemic variabilit : Should we and can we prevent it ?. *Diabetes Care*; 31 (Suppl. 2): S 150-54

Monnier L,Colette C, Owens DR, 2008. Glycemic variability: the third component of the dysglycemia in diabetes. Is it important ? How to measure it ? *J Diabets Sci Technol*: 2: 1094-1100

Moncada S, Higg EA,2006. Nitric oxide and vascular endothelium. *Handb. Exp Pharmacol.*; 176: 213-54.

- Manaf A, 2007. Chronic Acute Postprandial Hyperglycemia with Stress Oxidative : The background of Tissue Damage in Type 2 Diabetes Mellitus. Buku Pertemuan Ilmiah Berkala (PIB ) VIII Ilmu Penyakit Dalam, Padang 8-9 September.
- Manaf A, 2013. Postmeal hyperglycemia and vascular diabetic complications : the role of acarbose. Naskah lengkap. Pertemuan Ilmiah Berkala XIII Ilmu Penyakit Dalam, di Padang: p91-102.
- Manaf A, 2014. Prediabetes : The starting point to Fight Diabetes. Naskah lengkap Forum Endokrinologi dan Diabetes Sumatera-6. Padang : p10-27
- Manaf A, 2014. Tetrad concept in Glycemic Control : The role of Glucose Variability in Chronic Complications. Naskah lengkap Forum Endokrinologi dan Diabetes Sumatera-6. Padang : p131-41.
- Manaf A, 2014. Insulin Resistance as a Predictor of Worsening of Glucose Tolerance in Type 2 Diabetes Mellitus. *J Medicinus*; 27 (2): 3-8
- Moulds R, Lyn Learihan, Crawford K et al., 2009. Therapeutic Guidelines of Endocrinology, version 4 Expert group, Melbourne.
- Mogisshi 2008. Insulin Strategies for managing inpatients and outpatients hyperglycemic and diabetes. *Mt Sinai J Med* ; 75:558-66
- Mihm MJ, Jing L, Bauer JA, 2000. Nitrotyrosine causes selective vascular endothelial dys-function and DNA damage. *J Cardiovasc Pharmacol*; 36: 182-87
- Mardiyono B, Moeslichan S, Sastroasmoro W et al., 2011. Perkiraan besar sampel. Dalam : Sastroasmoro S, Ismael S, eds. Buku Dasar-dasar Metodologi Penelitian Klinis, ed 4; p 348-82
- Nishikawa T, Edelstein D, Du XL, et al., 2000. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycemic damage. *Nature* ;404:787-90
- Nathan DM, Buse JB, Davidson MB et al., 2006. Management of Hyperglycemia in Type 2 Diabetes : A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus statement from the ADA and the EASD. *Diabetes Care*; 29: 1963-72

Nathan DM et al.,2008. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for initiation and Adjustment of Therapy : Update Regarding Thiazolidinediones : A Consensus Statement from American Diabetes Association and the European Association for Study of Diadetes. Diabetes are 31; 173-75.

Node K, Inone T, 2009. Postprandial hyperglycemia as an etiological factor in vascular failure. Cardiovascular Diabetology; 8:23

Nakagami T,2004. Hyperglycemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia; 47 :385-94

Nigun A, Aylin SD, Cemile K,2006. Diabetes Mellitus and Oxidatif Stress. Turk Biyokimia Dergesi :31 (2) ; 55-56

Nesto, 2004. Corelation between cardiovascular disease and diabetes mellitus : current concepts. Am J Med; 116: 11S- 22S

PERKENI, 2011. Konsensus Penatalaksanaan Diabetes Melitus di Indonesia

PERKENI, 2015. Konsensus Penatalaksanaan Diabetes Melitus di Indonesia

Qian B, Wang H, Men X, 2008. TRIB 3 is implicated in glucotoxicity and oestrogen receptor stress-induced b cell apoptosis ; 199

Reusch JEB, 2003. Diabetes, microvascular complication and cardiovascular complication : what is about glucose ? Clin invest J ; 112: 986-88

Rudofsky G Jr, Reismann P, Schiekofer S, et al.,2004. Reduction of postprandial hyperglycemia in patients with type 2 diabetes reduces Nf-kappa B activation in PBMCs. Horm Metab Res; 36 :630-38

Rana , 2014. Hypoglycaemia and the cardiovascular system, Heart J ; 100: 21-7

Raza JA, Mohaved A,2003 Current Concepts of Cardiovascular diseases in diabetes mellitus. Intern J Cardiol;89 :123-34



Stumvold M, Golstein B, van Haeten T (2008 ). Pathogenesis of Type 2 DM. In: B.Goldstein and D Wieland. Type 2 Diabetes : Principles and Practice. New York

Syhabuddin S,2012. Acarbose in the prevention of Cardiovascular Complication of Prediabetes and Type 2 Diabetes. Naskah Lengkap PIB XII Ilmu Penyakit Dalam, Padang, p 104-09

Singh DK, Winocour P, Farrington K, 2010. Endothelial cell dysfunction, medial arterial calcification and osteoprotegerin in diabetes. Br.J Diabetes Vasc. Dis; 10: 71-77

Sena CM, PereiraAM, Seica R, 2013. Endothelial dysfunction- A major mediator of diabetic vascular disease. Review. Available online; [http:// dx.doi.org / 10.1016/j.bbadis2013.08.006](http://dx.doi.org/10.1016/j.bbadis2013.08.006) (diakses juli, 2014)

Sartore G, Chilelli NC, Burlina S, et al., 2013. Association between glucose variability as assessed by continuous glucose monitoring ( CGM) and diabetic retinopathy in type 1 and type diabetes. Acta Diabetol ;50: 437-42

Sorkin JD, Muller DC, Fleg JL, Andres R. 2005. The relationship of fasting and postchallenge plasma glucose concentration to mortality : Data from Baltimore Longitudinal Study of Aging with a critical review of literature. Diabetes Care ;28 (11): 2626-32

Saisho Y, 2014. Glycemic Variability and Oxidative Stress : A Link between Diabetes and Cardiovascular Disease ? a Review. Int J Mol Sci;15: 18381-18406.

Service FJ,Molnar GD,Rosevear JW et al., 1970.Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes;19:644-55

Oemijati S,Samsudin, Sutan Assin M et al., 2011. Penerapan etika penelitian kedokteran. Dalam : Satroasmoro S, Ismael S, eds. Buku Dasar-dasar Metodologi Penelitian Klinis, ed 4; p 383-90

Tjokropawiro A, 2012. Postprandial hyperglycemia in the progression of atherosclerosis : Therapeutic benefits of Dexanorm based on IDF Guideline 2007. Buku naskah lengkap PIB XII IPD,Padang; p 29-47

- Tjokroprawiro A, 2007. Diabetes mellitus klasifikasi, diagnosis dan terapi. Jakarta, Gramedia Pustaka Utama.
- Tushuizen M, Bunck M, Pouwel P, 2007. Pancreatic Fat Content and beta Cell Function in Men with and without type 2 diabetes; 30:2916-21
- Torimoto T, Okada Y, Mori H, et al., 2013. Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothel dysfunction in type 2 diabetes mellitus. Cardiovasc. Diabetol; 12: 1
- Thorell A, Hirsman M, Nygren J et al., 1999. Exercise and insulin cause GLUT-4 translocation in human skeletal muscle. Am J Physiol Endocrinol Metab; 277:733-41.
- UKPDS 33, 1998 : Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk complications in patients with type 2 diabetes. Lancet 352: 837-853
- Utzschneider U, Tong J, Montgomery W, 2008. The Dipeptidyl Peptidase-4 Inhibitor Vildagliptin Improves beta cell Function and Insulin Sensitivity in subjects with Impaired Fasting Glucose. Diabetes Care; 31:108-13
- Vasconcelos SML, Goulart MOF, Silva MAM et al., 2011. Markers of redox imbalance in the blood of hypertensive patients of community in northeastern Brazil. Arq Bras. Cardiol; 97: 141-47
- Valco M, Leibfritz D, Moncol J et al., 2007. Free radicals and antioxidants in normal physiological functions and human disease. IJBCB; 39:44-84
- World Health Organization, 2012. Available online : <http://www.who.int/diabetes/en> (diakses Pebruari 2012).
- Weyer C, Bogardus C, 1999. Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes; 48 :2197-2203
- Wei M, Gaskill SP, Haffner SM, et al., 1998. Effects of Diabetes and Level of Glycemia on All-cause and Cardiovascular Mortality : The San Antonio Heart Study. Diabetes Care ; 21: 1167-73
- Wascher T, 2005. Use of acarbose to control postprandial hyperglycemia in T2 DM. Eur J Clin Invest ;51: 551-57

WHO Consultation on Obesity, 2000. Obesity : Preventing and managing the global epidemic : Report of WHO Consultation. Technical report series. 894; 1-15.

Waspadji S, 2014. Advance in Glycemic Control : Benefits for Diabetics in Terms of Cardiovascular Outcomes. Naskah Lengkap Simposium Endokrinologi Klinik Bandung XI. Bandung.

Wheatcroft SB, Williams IL, Shah AM, et al., 2003. Pathophysiological implications of insulin resistance on vascular endothelial function. Diabet. Med.;20: 255-68.

Wilson JD, ed, 1998. In : Williams Textbook of Endocrinology. 9<sup>th</sup> Philadelphia : WB Saunders.

Xiao L, 2003. Oxidative Stress and Diabetes. The University of Iowa, IA 52242-1181.

Yerizal E, Manaf A, Yanwirasti, Oenzil F, 2012. Rerata aktivitas Poly ADP Ribose Polymerase (PARP ) pada kelompok penyandang DM Tipe 2. J Indon Med Assoc.;62:467-70.

Zang L, Lai E, Theodoro T, et al., 2009. GRP78, but not Protein-disulfide Isomerase, Partially reverse hyperglycemia- induced inhibition of insulin synthesis and secretion in pancreatic beta cell. JBC; 284:5289-98.

Zhou Y, Shimabukuro M, Koyama K, 1997. Induction by leptin of uncoupling protein-2 and enzymes of fatty acid oxidation; 94

Zick R, Schnitger F, Mainz V K, 2001. Acarbose reduces PPHG. J Horm Metab Res ; 34: 25-32.

Zhou J, Jia W, Bao Y et al., 2008. Glycemic variability and its response to intensive insulin treatment in newly diagnosed type 2 diabetes, Med Sci Monit ; 14(11): CR 552-8

